

- ✓ Page 19, line 13, please replace "acdi" with --acid--.
- ✓ Page 21, line 29, please replace "skilied" with --skilled--;
line 30, please replace "enyzmatic" with --enzymatic--.
- ✓ Page 25, line 32, please replace "effecting" with --affecting--.
- ✓ Page 28, line 13, please replace "spleen.y" with --spleen.--.
- ✓ Page 31, line 6, after "48" please insert --and--;
line 22, please replace "ng/mg" with --ng/mg)--;
line 26, please replace "ng/ml" with --ng/ml)--.
- ✓ Page 32, line 11, please replace "meonatal" with --neonatal--;
line 26, please replace "Shingomyelin(SM):EPC:CHOL" with
--Sphingomyelin(SM):EPC:CHOL--;
- ✓ Page 33, line 1, please replace "of³²P" with --of ³²P--;
line 2, between "i.v." and "made," please insert --was--.

IN THE CLAIMS:

✓ Please cancel claims 1-61.

Please add new claims 62-83:

-
- 1 ~~--62.~~ A method of treating a neoplasia in a mammal, said method comprising
2 administering to said mammal a pharmaceutical composition comprising a polyethylene glycol
3 (PEG)-ceramide conjugate, a lipid, and a nucleic acid catalyst, whereby a therapeutic result is
4 attained.
- 1 63. The method of claim 62, wherein the administration of said composition
2 results in a decrease in the expression of an RNA associated with said neoplasia in said
3 mammal.
- 1 64. The method of claim 62, wherein said neoplasia comprises a tumor.
- 1 65. The method of claim 62, wherein the administration is a systemic
2 administration.

1 66. The method of claim 62, wherein said composition further comprises
2 phosphatidyl choline.

1 67. The method of claim 66, wherein said phosphatidyl choline is egg yolk
2 phosphatidyl choline.

1 68. The method of claim 62, wherein said composition further comprises
2 cholesterol.

1 69. The method of claim 62, wherein said nucleic acid catalyst has an
2 endonuclease activity.

1 70. The method of claim 62, wherein said nucleic acid catalyst comprises a
2 ribonucleotide or a deoxyribonucleotide.

1 71. The method of claim 62, wherein said nucleic acid catalyst comprises a
2 hammerhead motif.

1 72. The method of claim 62, wherein said lipid is a cationic lipid.

1 73. The method of claim 72, wherein said cationic lipid is DODAC or DOTAP.

1 74. The method of claim 62, wherein said PEG-ceramide conjugate comprises a
2 fatty acid group having eight carbon atoms.

1 75. The method of claim 62, wherein said PEG-ceramide conjugate comprises a
2 fatty acid group having fourteen carbon atoms.

1 76. The method of claim 62, wherein said PEG-ceramide conjugate comprises a
2 fatty acid group having twenty carbon atoms.

1 77. The method of claim 62, wherein said nucleic acid catalyst specifically
2 cleaves vascular endothelial growth factor receptor (VEGF-R) RNA.

a
cont.